Abiomed (NSDQ:ABMD) today announced interim results of a study that found high-risk patients had better outcomes after implantation with its Impella CP heart pump. Data from the PROTECT III FDA post-approval study of Impella 2.5 and Impella CP in high-risk percutaneous coronary intervention (PCI) patients showed reduced rates of MACCE — a composite of death, stroke, […]
Abiomed
CMS rate cuts for Abiomed Impella not as bad as expected
CMS will pay 11% less for the tiny Impella heart pump made by Abiomed (NSDQ:ABMD) during the upcoming federal fiscal year — but the reduction is better than the 24% cut originally proposed. For the federal fiscal year ended Sept. 30, 2021, the rate for uni-ventricular Impella percutaneous insertion will be $71,950, down from the previous […]
Medtech stocks help boost S&P rally
Medtech stocks helped the S&P 500 Index reach record highs today amid a bounceback from the lows of the COVID-19 pandemic. Reuters reported that medtech played its part in the record turn of the market, with Abiomed (NSDQ:ABMD), Regeneron Pharmaceuticals (NSDQ:REGN) and West Pharmaceutical Services (NYSE:WST), all of which are involved in developing COVID-19 therapeutics, all rising more […]
MedTech 100 roundup: Another high as stocks tick up
For the third consecutive week, stocks in the medtech industry reached heights not yet seen since the COVID-19 pandemic began. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.65 points at the end of last week (Aug. 7). Overall, medtech stocks saw a 0.72% increase from […]
Abiomed shares slide on Street-beating Q1 results
Abiomed (NSDQ:ABMD) posted first-quarter results today that beat the consensus on Wall Street. The Danvers, Mass.-based company reported profits of $44.6 million, or 98¢ per share, on sales of $164.9 million for the three months ended June 30, for a bottom-line loss of -95% sales loss of -20.6% compared with Q1 2019. Adjusted to exclude one […]
FDA issues EUA for Abiomed Impella heart pumps for COVID-19 therapy
Abiomed (NSDQ:ABMD) announced today that the FDA issued emergency use authorization (EUA) for its Impella heart pumps in COVID-19 therapy. The EUA covers the left-sided Impella pumps in providing left ventricular unloading, supporting COVID-19 patients who are undergoing extracorporeal membrane oxygenation (ECMO) treatment and develop pulmonary edema or myocarditis, according to a news release. Impella, the […]
Abiomed touts results of U.S. study of its latest Impella heart pump
Abiomed (NSDQ:ABMD) says a study of U.S. patients receiving the new Impella 5.5 with SmartAssist found that 84% survived to explant and 76% experienced native heart recovery. The study — published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal — examined the outcomes of the first 55 patients treated with Impella […]
Abiomed appoints new chief medical officer
Abiomed (NSDQ:ABMD) today said it appointed Charles Simonton as VP and chief medical officer. Simonton most recently served as chief medical officer and divisional VP of global medical affairs at Abbott Vascular where he led programs that resulted in FDA approval of carotid stents, MitraClip and Absorb BVS. He has also spent almost 30 years as […]
FDA approves Abiomed’s Impella ECP clinical trial
Abiomed (NSDQ:ABMD) announced today that it received FDA investigational device exemption approval to begin a clinical trial for the Impella ECP heart pump. Impella ECP (expendable cardiac power) will be studied in the early feasibility, first-in-human trial for high-risk percutaneous coronary intervention (PCI) patients, according to a news release. The prospective, multi-center, non-randomized trial will assess […]
FDA issues EUA for Abiomed Impella RP to treat COVID-19 heart failure
Abiomed (NSDQ:ABMD) announced that it received FDA emergency use authorization (EUA) for its Impella RP for use with COVID-19-related right heart failure. The Impella RP temporary heart pump provides circulatory support for patients with right side ventricular failure. It won FDA approval in September 2017 for such an indication and in October 2019 Abiomed reported real-world data […]
Abiomed stock up amid Street-beating Q4 profits, news of Breethe acquisition
Abiomed (NSDQ:ABMD) shares are up 10% in morning trading today after the company posted Street-beating Q1 results and announced the acquisition of Breethe and its potential coronavirus-fighting tech. The Danvers, Mass.-based maker of circulatory support devices — including Impella heart pumps — posted profits of $31.8 million, or 70¢ per share, on sales of $206.7 million […]
